BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32358063)

  • 21. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.
    Singh AP; Arora S; Bhardwaj A; Srivastava SK; Kadakia MP; Wang B; Grizzle WE; Owen LB; Singh S
    J Biol Chem; 2012 Nov; 287(46):39115-24. PubMed ID: 22995914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
    Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
    Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer.
    Li X; Wang Z; Ma Q; Xu Q; Liu H; Duan W; Lei J; Ma J; Wang X; Lv S; Han L; Li W; Guo J; Guo K; Zhang D; Wu E; Xie K
    Clin Cancer Res; 2014 Aug; 20(16):4326-38. PubMed ID: 24947933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
    Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Duan W; Chen K; Jiang Z; Chen X; Sun L; Li J; Lei J; Xu Q; Ma J; Li X; Han L; Wang Z; Wu Z; Wang F; Wu E; Ma Q; Ma Z
    Cancer Lett; 2017 Jan; 385():225-233. PubMed ID: 27773749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Rückert F; Grützmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA
    Science; 2009 Jun; 324(5933):1457-61. PubMed ID: 19460966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
    Yin T; Zhang Z; Cao B; Duan Q; Shi P; Zhao H; Camara SN; Shen Q; Wang C
    Oncotarget; 2016 Jun; 7(24):37192-37204. PubMed ID: 27177084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
    Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
    de Sousa Cavalcante L; Monteiro G
    Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
    Onishi H; Morifuji Y; Kai M; Suyama K; Iwasaki H; Katano M
    Cancer Sci; 2012 Jul; 103(7):1272-9. PubMed ID: 22486854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
    Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
    Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
    Zhou T; Liu J; Xie Y; Yuan S; Guo Y; Bai W; Zhao K; Jiang W; Wang H; Wang H; Zhao T; Huang C; Gao S; Wang X; Yang S; Hao J
    Gut; 2022 Feb; 71(2):357-371. PubMed ID: 33674341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1.
    Zhou C; Qian W; Ma J; Cheng L; Jiang Z; Yan B; Li J; Duan W; Sun L; Cao J; Wang F; Wu E; Wu Z; Ma Q; Li X
    Cell Prolif; 2019 Jan; 52(1):e12514. PubMed ID: 30341797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
    Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
    Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway.
    Han L; Ma J; Duan W; Zhang L; Yu S; Xu Q; Lei J; Li X; Wang Z; Wu Z; Huang JH; Wu E; Ma Q; Ma Z
    Oncotarget; 2016 Apr; 7(14):18146-58. PubMed ID: 26934446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.